SDHAP1: A Potential Drug Target and Biomarker for ALZHEIMER'S DISEASE

Target Name: SDHAP1

NCBI ID: G255812

SDHAP1

Other Name(s): SDHALP1 | SDHA pseudogene 1 | SDHAL1

SDHAP1: A Potential Drug Target and Biomarker for ALZHEIMER'S DISEASE

Alzheimer's disease is a neurodegenerative disorder that affects millions of people worldwide, characterized by progressive memory loss, decline in cognitive function, and eventual death. The underlying cause of Alzheimer's disease is the accumulation of beta-amyloid plaques and neurofibrillary tangles in the brain, which cause neurotransmitter imbalances and neuro cell damage.

Recent studies have identified several potential drug targets and biomarkers for Alzheimer's disease. One of them is SDHAP1, a gene that encodes a protein known as SDHAP1. The function of SDHAP1 is not well understood, but its expression has been observed in the brains of individuals with Alzheimer's disease.

Initial studies suggested that SDHAP1 may be involved in the formation of beta-amyloid plaques and the neurofibrillary tangles that are hallmarks of Alzheimer's disease. Specifically, studies have shown that individuals with Alzheimer's disease have lower levels of SDHAP1 than healthy individuals. Additionally, inhibition of the activity of SDHAP1 has been shown to protect brain cells from beta-amyloid plaque formation in animal models of Alzheimer's disease.

Furthermore, some studies have suggested that SDHAP1 may be a potential biomarker for Alzheimer's disease. The accumulation of beta-amyloid plaques and neurofibrillary tangles in the brain is a hallmark of the disease, and there is a need for diagnostic tools that can accurately measure the level of these pathological changes in the brain. Several studies have shown that SDHAP1 levels are significantly decreased in the brains of individuals with Alzheimer's disease, which suggests that it may be a useful biomarker for the disease.

In addition to its potential as a drug target and biomarker, SDHAP1 is also of interest as a potential therapeutic target for Alzheimer's disease. The accumulation of beta-amyloid plaques and neurofibrillary tangles in the brain is a key event in the development and progression of Alzheimer's disease, and targeting SDHAP1 may provide new insights into the underlying mechanisms of the disease.

Overall, SDHAP1 is a promising drug target and biomarker for Alzheimer's disease. Further studies are needed to fully understand its role in the disease and its potential as a therapeutic target.

Protein Name: SDHA Pseudogene 1

The "SDHAP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SDHAP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets